Biotech Stocks Facing FDA Decision In June 2022

1 / 10

The FDA has approved only 15 novel drugs so far this year compared to 24 during the same period last year (Jan. to May).

The month of May saw the FDA approve Regeneron’s Dupixent as the first treatment for eosinophilic esophagitis, a chronic immune disorder.

Voquezna for Helicobacter pylori infection; Mounjaro to improve blood sugar control in adults with type 2 diabetes, as an adjunct to diet and exercise; and Vtama for plaque psoriasis are the three novel drugs that won approval in May.